We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice: A cohort study.
- Authors
Beermann, B.; Melander, H.; Säwe, J.; Ulleryd, C.; Dahlqvist, R.
- Abstract
Objective: To study the prescribing of the antiobesity drug orlistat in relation to the approved indication and its weight-reducing effect in clinical practice during the first 3 months of treatment. Methods: Anonymous postal questionnaire survey to prescribers of orlistat concerning a random sample of 1000 of 20,000 prescriptions. Participants: Useful information was obtained for 789 patients. Setting: Primary and secondary care in Sweden. Main outcome measures: Beginning and continued treatment according to the approved indication. Dropout from treatment. Weight loss during treatment. Results: Four percent of the patients were prescribed orlistat despite having a body mass index (BMI) less than 28 kg/m2. Only 24% of the patients had a diet period with a weight loss of 2.5 kg or greater before the start of therapy. Half of the patients with a weight loss of less than 5% after 3 months continued the treatment. Ten percent gained weight or had no weight loss at all while 43% lost less than 5% in weight. At least one-quarter of the patients stopped the treatment within the observation period. Conclusion: Orlistat was not prescribed according to the approved indication in the majority of cases. The dropout rate was high and most patients had minor gain from the treatment.
- Subjects
SWEDEN; ORLISTAT; CLINICAL medicine; ANTIOBESITY agents; HEALTH products; APPETITE depressants; PSYCHIATRIC drugs
- Publication
European Journal of Clinical Pharmacology, 2001, Vol 57, Issue 4, p309
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s002280100316